Combination therapy for advanced neuroendocrine cancer after first treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) added to a standard chemotherapy regimen called FOLFIRI, to see if it works better than FOLFIRI alone for a rare and aggressive type of cancer called neuroendocrine carcinoma. It is for people whose cancer has progressed after a first-line chemotherapy, and aims to help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must be a poorly differentiated neuroendocrine carcinoma (a rare, fast-growing type) that started in your digestive tract, pancreas, or an unknown place.
- You must have had one prior chemotherapy treatment with cisplatin (or carboplatin) plus etoposide, and your cancer must have progressed (grown) during or after that treatment.
- You must have at least one tumor that can be measured on a scan and that has not been previously treated with radiation.
- You must be in good enough physical condition to carry out daily activities (your doctor will check this).
- You and your partner must agree to use highly effective birth control during the study and for several months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
This study tests a new investigational drug called ZG006 against the chemotherapy your doctor would normally choose for advanced neuroendocrine carcinoma. The trial aims to see if ZG006 works better than standard chemotherapy for people whose cancer has progressed after earlier treatment.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
Hear when a new Carcinoma, Neuroendocrine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.